Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CGAS | Q8N884 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26913459 | 0.78 | CGAS (0.39) | CGASROCK2ROCK1 | |
| SCHEMBL26913021 | 0.78 | CGAS (0.41) | CGASROCK2ROCK1 | |
| SCHEMBL26912246 | 0.76 | CGAS (0.41) | CGASROCK2ROCK1 | |
| SCHEMBL26912789 | 0.76 | CGAS (0.40) | CGASROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL26912444 | 0.75 | CGAS (0.37) | CGASROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL26913350 | 0.75 | CGAS (0.37) | CGASROCK2ROCK1 | |
| SCHEMBL26912593 | 0.73 | CGAS (0.40) | CGASROCK2ROCK1 | |
| SCHEMBL26912976 | 0.71 | CGAS (0.40) | CGASROCK2ROCK1 | |
| SCHEMBL26913417 | 0.71 | ROCK2 (0.37) | ROCK2ROCK1 | |
| SCHEMBL26912305 | 0.70 | ROCK2 (0.38) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | CGAS 1/4885HPGD 1300/4885MAPK1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.